|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.26 USD | +0.21% |
|
+5.24% | +2.19% |
| 07-29 | Amarin Corporation plc, Q2 2026 Earnings Call, Jul 29, 2026 | |
| 07-29 | European Equities Traded in US as ADRs Ease in Wednesday Trading | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Development and Commercialization of Vascepa | 583M | 369M | 307M | 229M | 214M | |||||
Total Assets | 1.07B | 886M | 832M | 685M | 671M | |||||
Interest Expense | -129K | -15K | -8K | -7K | -7K | |||||
Income Tax Expense | 3.56M | 2M | 5.44M | 4.98M | 2.75M | |||||
CAPEX | - | -599K | -24K | - | - | |||||
EBT | 11.29M | -104M | -53.67M | -77.2M | -36.05M | |||||
Gross Profit | 462M | 242M | 166M | 81.38M | 121M | |||||
D&A | 2.86M | 3.1M | 2.96M | 3.01M | 3.03M | |||||
Operating Income | 10.5M | -106M | -67.59M | -91.8M | -50.17M | |||||
Net Income | 7.73M | -106M | -59.11M | -82.18M | -38.8M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
US | - | - | - | - | 154M | |||||
Unallocated | - | - | - | - | 30.89M | |||||
Europe | - | - | - | - | 18.37M | |||||
Rest of the World | - | - | - | - | 10.24M |
- Stock Market
- Stocks
- AMRN Stock
- Financials Amarin Corporation plc
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
